BIOG.L
The Biotech Growth Trust PLC [BIOG.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIOG.L Stock Summary
Top 10 Correlated ETFs
BIOG.L
Top 10 Correlated Stocks
BIOG.L
In the News
BIOG.L Financial details
Company Rating
Sell
Market Cap
333.24M
Income
-92.03M
Revenue
-87.66M
Book val./share
7.84
Cash/share
0.08
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
13 Jun 2024
P/E
-6.04
Forward P/E
-
PEG
1.15
P/S
-5.85
P/B
1.09
P/C
11775
P/FCF
-64.33
Quick Ratio
0.11
Current Ratio
0.11
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-2.32
EPS next Y
-
EPS next Q
-
EPS this Y
-78.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
NAN%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
0.25%
SMA50
4.55%
SMA100
27.72%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-25%
ROC
-0.18%
Gross Margin
100%
Oper. Margin
106%
Profit Margin
109%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
715.0-1078.74
52W High
-12.62%
52W Low
+31.75%
RSI
38.98
Rel Volume
1.24
Avg Volume
69.55K
Volume
86.14K
Perf Week
-2.59%
Perf Month
-4.27%
Perf Quarter
29.04%
Perf Half Y
22.98%
-
-
-
-
Beta
0.486
-
-
Volatility
16.11%, 12.77%
Prev Close
-0.63%
Price
942
Change
-2.48%
BIOG.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.42 | 1.41 | 5.1 | -5.06 | -0.93 | |
| Net income per share | 0.39 | 1.35 | 5 | -4.88 | -1.03 | |
| Operating cash flow per share | -0.08 | -0.08 | -0.14 | -0.29 | -0.15 | |
| Free cash flow per share | -0.08 | -0.08 | -0.14 | -0.29 | -0.15 | |
| Cash per share | 0 | 0 | 0.04 | 0 | 0.07 | |
| Book value per share | 7.51 | 8.1 | 15.02 | 9.51 | 8.2 | |
| Tangible book value per share | 7.51 | 8.1 | 15.02 | 9.51 | 8.2 | |
| Share holders equity per share | 7.51 | 8.1 | 15.02 | 9.51 | 8.2 | |
| Interest debt per share | 0.21 | 0.74 | 0.67 | 0.77 | 0.52 | |
| Market cap | 397.34M | 367.58M | 571.06M | 372.15M | 315.45M | |
| Enterprise value | 408.18M | 400.32M | 596.33M | 403.89M | 332.85M | |
| P/E ratio | 18.83 | 6.04 | 2.85 | -1.84 | -7.64 | |
| Price to sales ratio | 17.24 | 5.75 | 2.79 | -1.77 | -8.38 | |
| POCF ratio | -90.33 | -97.63 | -100.64 | -30.65 | -53.56 | |
| PFCF ratio | -90.33 | -97.63 | -100.64 | -30.65 | -53.56 | |
| P/B Ratio | 0.97 | 1.01 | 0.95 | 0.94 | 0.96 | |
| PTB ratio | 0.97 | 1.01 | 0.95 | 0.94 | 0.96 | |
| EV to sales | 17.71 | 6.27 | 2.92 | -1.93 | -8.84 | |
| Enterprise value over EBITDA | -101.54 | -96.65 | 196.42 | -150.14 | -62.3 | |
| EV to operating cash flow | -92.79 | -106.33 | -105.1 | -33.27 | -56.51 | |
| EV to free cash flow | -92.79 | -106.33 | -105.1 | -33.27 | -56.51 | |
| Earnings yield | 0.05 | 0.17 | 0.35 | -0.54 | -0.13 | |
| Free cash flow yield | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | |
| Debt to equity | 0.03 | 0.09 | 0.04 | 0.08 | 0.06 | |
| Debt to assets | 0.03 | 0.08 | 0.04 | 0.07 | 0.06 | |
| Net debt to EBITDA | -2.7 | -7.9 | 8.33 | -11.8 | -3.26 | |
| Current ratio | 0 | 0.07 | 0.13 | 0 | 0.11 | |
| Interest coverage | 29.86 | 111.48 | 1.1K | -1.14K | -46.33 | |
| Income quality | -0.21 | -0.06 | -0.03 | 0.06 | 0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.04 | 0.02 | -0.02 | -0.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.09 | 15.67 | 41.13 | 32.33 | 13.75 | |
| ROIC | 0.06 | 0.16 | 0.31 | -0.47 | -0.1 | |
| Return on tangible assets | 0.05 | 0.15 | 0.31 | -0.47 | -0.11 | |
| Graham Net | -0.41 | -0.75 | -1.07 | -0.8 | -0.67 | |
| Working capital | -22.3M | -33.08M | -41.8M | -33.19M | -26.94M | |
| Tangible asset value | 408.88M | 365.57M | 601.47M | 394.21M | 330.29M | |
| Net current asset value | -22.3M | -33.08M | -41.8M | -33.19M | -26.94M | |
| Invested capital | 0.03 | 0.09 | 0.04 | 0.08 | 0.06 | |
| Average receivables | 213K | 1.27M | 3.61M | 2.36M | 243.5K | |
| Average payables | 6.99M | 5.19M | 1.59M | 909K | 3.33M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0.62 | 14.25 | 8.44 | 0 | -4.72 | |
| Days payables outstanding | -521.43 | -131.39 | -28.07 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 590.9 | 25.62 | 43.25 | 0 | -77.32 | |
| Payables turnover | -0.7 | -2.78 | -13 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.05 | 0.17 | 0.33 | -0.51 | -0.13 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | -0.97 | -0.97 | -0.14 | -0.14 | |
| Net income per share | 0.45 | -0.98 | -0.98 | -0.18 | -0.18 | |
| Operating cash flow per share | -0.02 | -0.05 | -0.05 | -0.03 | -0.03 | |
| Free cash flow per share | -0.02 | -0.05 | -0.05 | -0.03 | -0.03 | |
| Cash per share | 0 | 0.07 | 0.07 | 0.08 | 0.08 | |
| Book value per share | 10.32 | 8.3 | 8.3 | 7.84 | 7.84 | |
| Tangible book value per share | 10.32 | 8.3 | 8.3 | 7.84 | 7.93 | |
| Share holders equity per share | 10.32 | 8.3 | 8.3 | 7.84 | 7.84 | |
| Interest debt per share | 0.63 | 0.01 | 0.51 | 0 | 0.31 | |
| Market cap | 405.36M | 368.5M | 311.59M | 301.29M | 290.44M | |
| Enterprise value | 430.82M | 365.72M | 328.99M | 298.16M | 298.74M | |
| P/E ratio | 5.48 | -2.35 | -1.99 | -10.97 | -10.57 | |
| Price to sales ratio | 18.09 | -9.54 | -8.07 | -57.76 | -55.68 | |
| POCF ratio | -447.18 | -180.77 | -152.85 | -321.9 | -310.3 | |
| PFCF ratio | -447.18 | -180.77 | -152.85 | -321.9 | -310.3 | |
| P/B Ratio | 0.96 | 1.12 | 0.94 | 1.03 | 0.99 | |
| PTB ratio | 0.96 | 1.12 | 0.94 | 1.03 | 0.99 | |
| EV to sales | 19.23 | -9.47 | -8.52 | -57.16 | -57.27 | |
| Enterprise value over EBITDA | -154.83 | 721.35 | 648.89 | -424.43 | -425.26 | |
| EV to operating cash flow | -475.26 | -179.41 | -161.39 | -318.55 | -319.17 | |
| EV to free cash flow | -475.26 | -179.41 | -161.39 | -318.55 | -319.17 | |
| Earnings yield | 0.05 | -0.11 | -0.13 | -0.02 | -0.02 | |
| Free cash flow yield | 0 | -0.01 | -0.01 | 0 | 0 | |
| Debt to equity | 0.06 | 0 | 0.06 | 0 | 0.04 | |
| Debt to assets | 0.06 | 0 | 0.06 | 0 | 0.04 | |
| Net debt to EBITDA | -9.15 | -5.47 | 34.32 | 4.46 | -11.82 | |
| Current ratio | 0 | 0.11 | 0.11 | 0.3 | 0.3 | |
| Interest coverage | 156.6 | -152.47 | -152.47 | 0 | 0 | |
| Income quality | -0.05 | 0.05 | 0.05 | 0.14 | 0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | -0.02 | -0.02 | -0.14 | -0.14 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 10.26 | 13.55 | 13.55 | 5.69 | 5.69 | |
| ROIC | 0.05 | -0.12 | -0.11 | -0.02 | -0.02 | |
| Return on tangible assets | 0.04 | -0.11 | -0.11 | -0.02 | -0.02 | |
| Graham Net | -0.68 | -0.68 | -0.68 | -0.31 | -0.21 | |
| Working capital | -27.73M | -26.94M | -26.94M | -10.39M | -10.39M | |
| Tangible asset value | 420.73M | 330.29M | 330.29M | 293.42M | 296.77M | |
| Net current asset value | -27.73M | -26.94M | -26.94M | -10.39M | -7.03M | |
| Invested capital | 0.06 | 0 | 0.06 | 0 | 0.04 | |
| Average receivables | 12.5K | 256K | 487K | 243.5K | 638K | |
| Average payables | 0 | 3.1M | 6.21M | 3.1M | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | -638K | |
| Days sales outstanding | 0.1 | -1.14 | -1.14 | 0 | -22.02 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 896.12 | -79.28 | -79.28 | 0 | -4.09 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.04 | -0.12 | -0.12 | -0.02 | -0.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BIOG.L Frequently Asked Questions
What is The Biotech Growth Trust PLC stock symbol ?
The Biotech Growth Trust PLC is a US stock , located in New york of Ny and trading under the symbol BIOG.L
What is The Biotech Growth Trust PLC stock quote today ?
The Biotech Growth Trust PLC stock price is $942 today.
Is The Biotech Growth Trust PLC stock public?
Yes, The Biotech Growth Trust PLC is a publicly traded company.
Company Profile
- Volume Average 69.55K
- Market Capitalization 333.24M
- CEO Mr. Samuel David Isaly
- Headquarters New York,NY,US
- IPO Date 1997-06-23
-
Website
https://www.biotechgt.com/index.php/biog/home/overview/ 
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.
